Welcome to our dedicated page for Zhongchao news (Ticker: ZCMD), a resource for investors and traders seeking the latest updates and insights on Zhongchao stock.
Zhongchao Inc. reports developments as a Cayman Islands holding company whose PRC operating entities provide platform-based healthcare information, education, training, patient management, and internet healthcare services in China. Its updates center on cancer and major-disease services, including the MDMOOC professional education platform, Zhongxin patient management programs, Zhixun Internet Hospital, and Sunshine Health Forums.
Recurring news themes include patient aid and medication assistance projects, disease management models for oncology and autoimmune conditions, healthcare professional education platforms, content partnerships for cancer education, and ordinary-share consolidations tied to Nasdaq listing compliance for ZCMD Class A ordinary shares.
Zhongchao Inc. (NASDAQ: ZCMD) announced the launch of the Medication Management Assistance Mini Program via WeChat, aimed at aiding cancer patients in managing their medication during treatment. The Program addresses challenges such as dosing punctuality and adverse reaction management by providing automated reminders and self-treatment information based on individual cancer types. Initially focused on lung and kidney cancer, the Program plans to expand to include other cancers. CEO Weiguang Yang emphasized the importance of patient education and adherence for better treatment outcomes, aiming to enhance the overall patient service experience.
Zhongchao Inc. (NASDAQ: ZCMD) announced a partnership with Chongqing Xinjiang Pharmaceutical Co., Ltd. to distribute Natco Pharma Limited's products in China. The collaboration aims to address patient needs by introducing various drugs, including anti-influenza and anti-tumor medications. Both companies will expedite clinical trials and regulatory processes to enhance drug availability. CEO Weiguang Yang emphasized the importance of this partnership in improving healthcare access in China. This move aligns with Zhongchao's mission to enhance service models for oncology and major diseases.
Zhongchao Inc. (NASDAQ: ZCMD) has launched its "Surgical-Interventional-Drug" (SID) platform aimed at enhancing liver cancer physician education in response to rising cases in China, where around 400,000 new liver cancer cases were reported in 2020. Designed to support comprehensive management and treatment strategies, the SID Platform has been accessed approximately 290,000 times by physicians. This initiative aligns with the National Health Commission's treatment guidelines and aims to improve ongoing professional development for healthcare providers, ultimately benefiting liver cancer patients.
Zhongchao Inc. (NASDAQ: ZCMD) announced that its operational entity, Chongqing Xinjiang Pharmaceutical Co., Ltd., has secured multiple pharmaceutical licenses, paving the way for expansion into the pharmaceutical market. These include a Pharmaceutical Trade License and a Medical Device Trade License. The company aims to enhance its 'Medical-Pharmaceutical-Patient' model, addressing oncology and major diseases. With an eye on strengthening its market presence, Xinjiang Pharmaceutical will engage in drug import/export and online pharmaceutical services, supported by extensive partnerships and educational resources.
Zhongchao Inc. (NASDAQ: ZCMD) announced the establishment of Chongqing Xinjiang Pharmaceutical Co., Ltd. to enhance the accessibility and affordability of medications for patients with oncology and other major diseases. This new entity aims to streamline pharmaceutical procurement via a 2B2C platform, collaborating with Zhixun Internet Hospital and others. The initiative is part of Zhongchao's strategy to expand its 'Medical-Pharmaceutical-Patient' model, addressing growing patient-oriented healthcare demands in China. The company seeks to improve drug delivery and patient experience.
Zhongchao Inc. (NASDAQ: ZCMD) announced the launch of its subsidiary Zhixun Internet Hospital in Liaoning, aimed at providing standardized Internet healthcare services for oncology and major diseases. This initiative enhances Zhongchao's patient management capabilities by offering comprehensive services, including remote consultations and follow-up visit management. The All-in-One Service model aims to improve treatment continuity and patient outcomes. Chairman Weiguang Yang emphasized the importance of connecting in-hospital and out-of-hospital services to enhance the quality of medical care.
Zhongchao Inc. (NASDAQ: ZCMD) has announced a strategic shift to expand its business model from 'Medical-Pharmaceutical' to 'Medical-Pharmaceutical-Patient', focusing on oncology and major disease management. The company launched its patient management business in 2021, achieving a 40.4% improvement in Duration of Therapy for liver cancer patients using its self-developed system. Over hundreds of thousands of patients have benefited from disease management services. CEO Weiguang Yang emphasized the commitment to digital innovation in healthcare to enhance patient outcomes and drive shareholder value.
Zhongchao Inc. (NASDAQ: ZCMD) announced the launch of its MDMOOC platform's online training course titled "Disease Prevention and Distribution Quality Management," aimed at enhancing skills in vaccination management for up to 20,000 healthcare staff. The course, launched in April 2022, is accessible through the MDMOOC website and WeChat platforms. Industry experts from various locations will lead the course, addressing key aspects of disease control and public health. Zhongchao remains committed to providing timely training for medical professionals in response to pandemic-related challenges.
Zhongchao Inc. (NASDAQ: ZCMD) reported a 94.6% decline in net income to $238,665 for the fiscal year 2021, down from $4.46 million in 2020. Revenues fell 9.4% to $16.30 million, primarily due to reduced income from medical training and education services. Gross profit also decreased by 20.5% to $9.44 million, leading to a gross margin decline of 8.1 percentage points. Operating expenses rose 32.2% to $9.76 million, driven by significantly increased general and administrative costs.
Zhongchao Inc. (NASDAQ: ZCMD) announced that its innovative patient management system has significantly improved the Duration of Therapy (DOT) by 40.4% for liver cancer patients. This improvement enhances drug efficiency and supports longer patient survival rates. The system aids nearly 20,000 patients in managing their treatment through education, follow-ups, and psychological support. With 400,000 new liver cancer cases reported in China in 2020, this advancement has the potential to notably impact patient outcomes and overall healthcare efficiency.